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ABSTRACT
The discovery of RNA interference in C. elegans in 1998 has established this nematode
as a key model to study RNAi mechanisms. Meanwhile, RNAi has been extensively applied to
study a variety of basic biological questions in worms. In C. elegans, the dsRNA required to
trigger RNAi can be administered by injection, by soaking, and importantly, by feeding. The
delivery of dsRNA through food and the existence of two RNAi feeding libraries allow for large
scale RNAi approaches. Thus, RNAi libraries have been used to screen for genes related with
processes as diverse as embryonic development, longevity, fat accumulation, DNA damage
response, axon guidance or synapse structure, among others. Moreover, since RNAi facilitates the
inactivation of more than one gene at the time in the same animal, RNAi assays are being applied
to uncover genetics interactions among genes and therefore there is a significant and ongoing
progress in identifying components of genetics pathways and networks.
Here we review successful applications of RNAi as tool in C. elegans research, and discuss trends
in using such tool to shed light into several biological research fields.
Introduction
Commonly, the function of a gene is inferred by studying the phenotype resulting from
its loss of function or its partial loss of function. Studying the function of a given gene has been a
daily task for thousands of researchers in the last 40 years. This previously laborious work can
now be done in just few days thanks to RNAi, which is a mechanism to inactivate a gene triggered
by dsRNA gene specific. RNAi was first characterized in C. elegans at the same time that the C.
elegans genome was published (first metazoan genome sequenced)[1, 2]. These events occurred in
1998 and gave a leading role to C. elegans as model organism for biological research. Nine years
later, we here review the extraordinary impact that RNAi is having in leading a golden decade in
C. elegans research. We first review the RNAi pathway and how modifications of pieces within
the RNAi machinery may be relevant to obtain an optimal yield of RNAi as technique. Sydney
Brenner conceived this model organism as ideal to understand the nervous system [3] and we
present a section on RNAi assays that have contributed to analyze neuronal functions in C.
elegans. We also review the impact of RNAi-based projects in C. elegans to study issues that
concern to humans such us embryonic development, aging and cancer. Finally, we present the
groundbreaking effect that C. elegans RNAi is having in systems biology.
Throughout this chapter we will mention some of the great characteristics of C. elegans as a model
organism.  These include its short life cycle, easy and cheap maintenance (fed with E. coli and
grown on agar in Petri dishes), transparent body, ability to self-fertilize as well as to cross with
males that facilitate genetics, stereotyped somatic cell lineages, capability of being frozen and
thawed, and state-of-the-art genomics tools. This and much more about C. elegans, including
databases of RNAi phenotypes, can be found in www.wormbase.org, which is the main online
resource for C. elegans researchers [4].  Additional introductions to most fields of C. elegans
research can also be found in the collection of reviews available at www.wormbook.org.
Applications of RNAi mechanisms nuances
Since 1998, when Andy Fire and collaborators published in Nature a "Potent and
specific genetic interference by double-stranded RNA in Caenorhabditis elegans" [2], scientists
are squeezing all the fresh information published on RNAi mechanisms to get an optimal
efficiency and expand the applicability of this revolutionary experimental tool. As examples, C.
elegans researchers are now able to conduct RNAi assays in a tissue-specific manner or in strains
with hypersensitivity to RNAi.
Fire and co-workers observed how injection of dsRNA into worm gonads induced a sequence
specific silencing of the corresponding gene. With the help of valuable research in C. elegans,
plants and Drosophila, details of RNAi mechanisms have been revealed in the past few years [5,
6]. Once dsRNA is inside the cell, a protein called Dicer slices it to produce small dsRNA
molecules of 21-22 nucleotides known as siRNAs. Each siRNA has a “sense” strand (sequence
identical to the target gene) that is eliminated and an “antisense” strand (sequence complementary
to the target gene) that guides the protein complex RISC to degrade the mRNA transcribed from
the targeted gene. RNAi silencing effect was initially thought to happen only through mRNA
degradation but two more mechanisms were uncovered acting by blocking transcription [7, 8] and
by inhibiting translation [9, 10].
Interestingly, siRNAs are defensive weapons that the eukaryotic cell uses to fight dsRNA viruses
and other harmful influences for its genome such as transposons (mobile elements) and repetitive
sequences (as transgenes). Thus, worms carrying mutations in genes related with RNAi process
are often unable to silence transposons or transgenes in germline tissues [8, 11].
Rather than digging into details of RNAi mechanisms, in this section we intend to list and
comment on RNAi mechanism nuances that allow us to profit from RNAi as technique.
A remarkable feature of RNAi in C. elegans is the systemic spread of the induced silencing. In
other words, application of dsRNA in one part of the animal can produce an RNAi effect in distant
tissues. Scientists soon exploited this phenomenon to trigger a systemic RNAi response by soaking
worms in dsRNA solution and by feeding worms with bacteria expressing dsRNA [12, 13].
Administration of dsRNA by soaking is more expensive and less reliable than feeding (Fernandez
and Piano, personal communication). Moreover, there are two complementary RNAi feeding
libraries, commercially available and widely distributed, containing feeding clones to inactivate
approximately 86% of the C. elegans genes [14, 15]. These libraries were generated in Julie
Ahringer and Marc Vidal labs using as template to synthesize dsRNA genomic DNA and a cDNA
library respectively. As consequence, dsRNA by feeding is a technique performed in most of the
C. elegans labs routinely. Conveniently RNAi by feeding allows for modulation or titration of the
RNAi effect by diluting the bacteria [16, 17]. Interestingly, although the RNA machinery is
capable of being saturated, combinatorial RNAi (simultaneous targeting of two different genes)
have effectively been developed [16].
The phenomenon of systemic RNAi, or RNAi spreading, has been studied by identifying mutants
in which systemic RNAi is impaired [18, 19]. Detailed analysis of these mutations will clarify the
spreading process. One of the genes affected for these mutations is sid-1, which encodes a
transmembrane protein required for the uptake of dsRNA. In the absence of SID-1 protein, dsRNA
can still trigger RNAi in cells where is injected or endogenously synthesized, but it is not effective
in other neighboring or distant cells.
Since RNAi spreading is absent from mammalian species, the obvious project after the
identification of SID-1 was to express SID-1 in mammalian cells to make them susceptible to
systemic RNAi. Unfortunately, this transmembrane protein seems to have an optimal uptake for
long dsRNA molecules and it is very inefficient for siRNAs uptake, which are the molecules
required to trigger RNAi in mammalian cells without inducing interferon responses [20]. To date,
mutant worms identified as defective in systemic RNAi are viable and do not appear to show any
additional phenotype. These healthy mutants facilitate its use as genetic background for
experiments that require abolishment of RNAi spreading to perform RNAi cell or tissue specific.
As example Briese et al recently took advantage of sid-1mutants to substantially reduce but not
abolish the spreading of the RNAi signal, triggered from promoter-driven hairpins, from neurons
to muscle [21].
In C. elegans RNAi is heritable because the silencing effect can be observed through several
generation depending on the targeted gene [2, 22]. This phenomenon may be explained by a
dilution of the trigger. However, the Plasterk lab has recently observed that a single episode of
RNAi can induce long term transcriptional silencing effects that are inherited in the absence of the
original trigger [23]. Vastenhouw and co-workers injected ceh-13 dsRNA into wild-type N2
worms to induce a small and dumpy phenotype that persist indefinitely, although inheritance was
not fully penetrant since only 30% of the animals of each generation was small and dumpy. Beside
ceh-13, they tested other 171 genes and only 13 (including dpy-6, dpy-28 and unc-73) could be
inheritably silenced. In practical terms, if you are interested in a particular postembryonic
phenotype, it seems probable that a single dsRNA trigger could allow keep the phenotype of
interest indefinitely. Mechanistically, these findings are quite significant since authors also found
that four genes related with chromatin remodelling were required for the RNAi effect inheritance.
Moreover, the rde-1 and rde-4 genes are essential for the RNAi mechanism, but dispensable to
RNAi inheritance [22]. All together, these observations suggest that siRNAs may be responsible
for the inheritance of the RNAi effect through its silencing activity at the transcriptional level.
Identification of functional elements inhibiting or activating the efficacy of the RNAi pathway has
allowed the use of mutations to enhance or inhibit the RNAi effect. Here we comment on how
mutations for rde-1, eri-1, rrf-1 and rrf-3 have experimentally been used to modify the standard
RNAi response.
The Dicer complex, which is responsible for producing siRNA from exogenous dsRNA, contains
several proteins including DCR-1 and RDE-1 (PAZ-PIWI family protein) [24]. Both DCR-1 and
RDE-1 proteins are required for RNAi, however mutations in the dcr-1 gene cause sterility while
rde-1 mutants are viable and do not exhibit any apparent phenotype except for reduced RNAi
susceptibility. The absence of phenotype in rde-1 mutants had been used for two purposes: to
perform tissue-specific RNAi and to observe postembryonic phenotypes for genes that normally
cause embryonic lethality when inactivated. The strategy to perform tissue-specific RNAi consists
in tissue-specific expression of the wild type rde-1 cDNA in rde-1 mutants, confining the RNAi
sensitivity to a specific tissue or cell lineage. This approach has already been successfully applied
by expressing rde-1 cDNA under control of the lin-26 and hlh-1 promoters, which are specific for
hypodermis and muscles respectively [25]. The second application of rde-1 mutant helps to
overcome RNAi induced embryonic lethality and observe a postembryonic phenotype. The trick is
to inject the dsRNA of interest in rde-1 hermaphrodites and cross them with wild type males [11].
RNAi will not occur in hermaphrodites and all maternal product corresponding to the targeted
gene will be kept intact allowing overcome the embryonic stage. However, cross progeny will
contain a wild type copy of rde-1 (provided by the male progenitor) that it is sufficient to trigger
the RNAi response at postembryonic stages. An alternative method to observe postembryonic
phenotypes would be to deliver RNAi by feeding L1 animals, but often administration of dsRNA
by injection is more effective.
In some organisms, including C. elegans, gene silencing by RNAi requires the activity of RNA-
dependent RNA polymerase (RdRPs) in an amplification step that synthesizes more siRNA
(secondary siRNA) using the antisense strand of an siRNA as a primer. In fact, recently it has been
shown that secondary rather than primary siRNAs may play a major role in the destabilization of
target transcripts during RNAi in C. elegans [26].
There are two well characterized C. elegans RdRPs called ego-1 and rrf-1 that are required for
RNAi in the germline and somatic tissues respectively [27, 28]. Thus, RNAi assays in mutants for
these genes could help to discriminate whether a resulting RNAi phenotype originates from a
defect in somatic or germ cells.
In addition, there are proteins such as ERI-1 and RRF-3 that act as endogenous inhibitors of RNAi
in C. elegans, and therefore, their inactivation enhances the RNAi response [29, 30]. The gene eri-
1 encodes a ribonuclease that may have siRNAs as substrate since eri-1 mutants accumulate
higher levels of antisense strand siRNA than wild type animals. eri-1 gene is expressed
preferentially in neurons and in the somatic gonad, which might be one of the reasons for the
reduced efficiency of RNAi in neuronal cells. The other inhibitor of the RNAi pathway, rrf-3, is a
member of a family of proteins with homology to RdRPs. The mechanism of action of RRF-3 is
still unknown but RRF-3 may compete with other RdRPs such as EGO-1 and RRF-1 for
components of the RNAi pathway [31]. Both eri-1 and rrf-3 present phenotypes as temperature-
dependent sterility and high incidence of males, underlining the possibility of these genes acting in
the same RNAi opposing pathway. Microarray analysis of genes regulated by rrf-3 and eri-1 had
recently showed that there are 72 transcripts that there are overexpressed in mutants for these two
genes compared to N2 wild type strain. This study supports the hypothesis of both genes acting
together in an endo-siRNA pathway [32].
 The rrf-3 mutant strain has been used as RNAi hypersensitive background to run a genome-wide
RNAi library that was previously assayed in wild type worms, identifying additional phenotypes
for 393 genes [33]. As a result, using the rrf-3 strain is a common strategy used by C. elegans
researchers when RNAi against their gene of interest does not show any phenotype in wild-type
worms.
Class B genes of the synthetic multivulva pathway (vulva cell fate pathway requires activities of
both SynMuv A and synMuv B genes) have also been identified as inhibitors of the RNAi
pathway [34, 35]. synMuv B genes seems to operate in parallel to the putative pathway shared by
eri-1 and rrf-3 as combinations of mutations in these two pathways result in enhanced
hypersensitivity to RNAi compared to that of the respective single mutants.
One hypothesis is that inactivation of synMuv B genes may act by repressing the expression of
germline genes, as ego-1, in the soma. Similarly to rrf-3 mutants, a large-scale RNAi assay was
also performed in RNAi hypersensitive mutant animals for the synMuv B gene lin-35 Rb. Out of
10953 genes targeted, 523 showed an enhanced RNAi phenotype in lin-35 Rb mutants including
57 genes that were putative synthetic lin-35 Rb interactors [36]. As a result of the same study, the
zinc finger protein ZFP-2 was identified as a gene that interacts genetically with lin-35 Rb during
C. elegans development. Interestingly, zfp-2 mutants are also hypersensitive to RNAi. For the
purpose of this chapter, a third interesting outcome of this study is that RNAi sensitivity of RNAi
hypersensitive strains is gene specific, which is in agreement with other recent findings [34, 35].
As an example, mom-2 RNAi produces higher embryonic lethality in zfp-2 (tm557) than in rrf-3
(pk1426), but unc-15 RNAi produces uncoordinated animals in the rrf-3 (pk1426) background but
wild type worms in zfp-2 (tm557).
The number of chromatin-related genes that may inhibit the RNAi pathway may be
underestimated since, differently from zfp-2 and lin-35, many play other functions essential for
viability. The mechanisms of these genes in regulating the RNAi pathway remains unclear, but
given the predicted nuclear location of these proteins it seem possible that they influence silencing
at the transcriptional level, where the antisense strand of siRNA bind to complementary sequences
in the genome.
We have briefly reviewed experimental approaches that took advantage of the knowledge about
RNAi mechanisms. There are many more genes that are functionally related with the RNAi
process. The Ruvkun lab, through a very elegant screen, has identified 90 genes whose
inactivation alters the efficacy of RNAi [37]. Among these 90 genes are 11 known components of
the RNAi machinery. Functional studies on the remaining 79 genes will shed light on RNAi
functional networks and will contribute to further development of RNAi as an experimental
technique to inactivate gene functions.
There are many advantages in using RNAi but there are also potential problems that should be
taking into account when interpreting RNAi data. RNAi is subjected to off-target cross-reaction. In
other words, RNAi can affect other genes with sequence similarity to the targeted gene producing
false positives. Rual et al predicted that cross-reaction occur when an mRNA sequence shares
more than 95% identity over 40 nucleotides [38]. Others researchers set the threshold to consider a
possible cross-reaction in 80% of identity over 200 nucleotides [39]. In any case, a hit obtained
from an RNAi screen suspicious of having off-targets effects must be filtered, validated and
supported with additional experiments. False negatives or missing RNAi effects are also frequent
but are highly dependent on the RNAi protocol followed and how carefully the phenotype is
observed and scored. In summary, by deciphering the RNAi pathway we have learned that it can
be influenced in many diverse ways and that each biological question addressable by RNAi in C.
elegans has an optimal way to be successfully performed.
RNA interference in C. elegans nervous system
The nematode C. elegans emerges as an excellent model to study any aspect of nervous
system physiology, molecular and cell biology. The fact that this organism has an invariable
number of neurons (302 in the hermaphrodite and 381 in the male), all its synapses are mapped
and its axons and dendrites are typically unbranched enormously facilitates any experimental
approach aimed to understand the mechanisms that control nervous system development [40].
Furthermore, the transparency of the animal allows the labelling of neurons in vivo by using
fluorescent proteins paving the way to genetic screens in the nervous system by simple direct
visual inspection. More importantly, given that more than 50% of the human disease genes have
clear orthologues in C. elegans genome, this model is particularly suitable to identify genes
involved in most of human neurodegenerative and neuromuscular diseases [41].
Inconveniently, in C. elegans not all tissues respond equally to the spreading of RNAi, with the
nervous system being the most refractory tissue to this mechanism for reasons which are still not
fully understood [42]. To overcome the limitations of RNAi induction in neurons, several
approaches have been attempted. Initially, Tavernarakis and collaborators developed a strategy
based on the expression of a hairpin dsRNA encoded in a transgene under the control of a strong
ubiquitous promoter induced by heat-shock [43]. This method, although it proved effective, had
the inconvenience that the gene knock-down can not be induced in a cell-specific fashion.
Subsequently, modifications of this approach were developed by using cell-specific promoters but
the efficiency and reproducibility of this method was not fully satisfactory due to concerns about
the stability of the plasmid and the transgene carrying the inverted repeated gene [21]. More
recently, Esposito and colleagues have reported an efficient and neuron-specific knock-down
protocol based on the expression of sense and antisense RNA molecules of a given gene under the
control of a neuron-specific promoter [44]. This procedure consists of three sequential steps: a)
Separate PCR amplification of the neuron-specific promoter and the sense and antisense sequences
of the gene, b) fusion of the gene sequences to that of the promoter by nested primer PCR and c)
mix of the fused PCR products in equimolar amounts and injection into worms. This method has
the advantage of overcoming the stability and reproducibility problems described above for the
transgene hairpin dsRNA strategy.
A completely different tactic, also aimed to overcome the problems of the inefficiency of RNAi in
neurons, consisted in the search of mutations that enhanced the sensitivity of the worm nervous
system (and other tissues) to the RNAi effect. Genetic screenings devised with this objective
resulted in the identification of genes such as rrf-3, eri-1, lin-15b and lin-35  (these two
components of the retinoblastoma pathway) or nre-1 that, when inactivated, rendered worms
hypersensitive to the effects of RNAi in neurons [29, 30, 34, 35, 45]. Among those, eri-1 and rrf-3
are the more commonly used backgrounds in genome-wide RNAi analyses. The recently identified
nre-1 mutation has not yet been mechanistically characterized although the fact that it shares the
temperature-dependent sterility phenotype found eri-1 and rrf-3 mutants indicates that this gene
might participate in the same pathway down-regulating the RNAi response [45].
The identification of mutations that hypersensitized the worm nervous system to the effect of
RNAi raised the question of whether the different C. elegans neurons display selective sensitivity
to RNAi. Asikainen and colleagues addressed this question by evaluating the RNAi effectiveness
using GFP reporters expressed in different neuron subtypes classified by the neurotransmitter they
use [46]. These authors found that GABAergic and dopaminergic neurons are more resistant to
RNAi than cholinergic, glutamatergic and touch neurons, independently of their location along the
animal. The fact that neurons of the same subtype are sensitive to RNAi while others are not,
indicates that the selective sensitivity of C. elegans neurons to RNAi is likely the result of cell-
specific properties rather than the neurotransmitter used. Interestingly, the sensitivity of neuronal
types to RNAi is largely independent of the route of dsRNA administration [46].
For a while, the refractory properties of C. elegans nervous system to RNAi somehow hampered
the development of genetic screenings aimed to identify key players of different aspects of
nervous system physiology and function. However, the characterization of the previously
described mutations that sensitized worm neurons to RNAi has allowed an important advance in
genome-wide screenings specifically designed for this purpose. And it is in the context of nervous
system specific RNAi screenings where C. elegans offers a fantastic potential as an in vivo tool.
For instance, a genome-wide RNAi analysis using the strain rrf-3 resulted in a 23% increase in the
number of genes for which a phenotype was scored, compared to the same screening using the N2
wild-type strain. Interestingly, known phenotypes were detected for many more neuronally
expressed genes in the rrf-3 background [33]. Other screenings using hypersensitive strains have
resulted in the identification, for example, of novel axon guidance genes [45] or genes required for
synapse structure and function [47].
Despite its apparent simplicity, C. elegans displays a wide variety of active behavioral responses
such as locomotion, feeding, chemotaxis, thermotaxis, reproduction, egg-laying, defecation, etc,
performances that are under control of tight neuronal regulation [48]. Indeed, inactivation of
neuronal genes either by RNAi or mutation causes defects in many of the above mentioned
behaviors resulting in phenotypes associated to nervous system dysfunctions [48, 49]. Together
with the fact, previously mentioned, that more than 50% of the human disease genes are present in
C. elegans, and that many of the classical vertebrate neurotransmitters are also used in the worm
nervous system, genetic screens with the hypersensitive strains offer a unique system for high-
throughput RNAi approaches. These studies will aim to discover novel drug or therapeutic agents
that modulate many aspects of these and other behaviors and, more importantly, contribute to the
identification of key molecular components in C. elegans models of neurodegenerative and
neuromuscular diseases.
Such an application of RNAi worms can be exemplified in the case of a worm model of
Huntington´s disease (HD). This neurodegenerative disease is characterized by a neuronal cell
degeneration mainly in the frontal lobes of the brain resulting in jerky, random and uncontrollable
movement on the individuals which is also accompanied by progressive impairment of cognitive
abilities [50]. HD is caused by expansion of a polyglutamine (polyQ) tracts in the huntingtin
protein, whose normal function is unknown, leading to neurodegeneration that is dependent on the
length of the polyQ tract [50]. A C. elegans HD transgenic model has been constructed by
heterologous expression of a fragment of huntingtin expanded polyQ causing neuronal
malfunctioning and formation of intracellular aggregates [51]. A genome-wide RNAi screen has
been conducted in this transgenic model which has resulted in the identification of several
regulators of polyglutamine aggregation such as genes involved in protein synthesis, folding and
aggregation as well as protein trafficking [52]. In a recent report, a high- throughput approach used
a C. elegans HD transgenic strain in a search for potential therapeutic drugs that could suppress
the neurotoxicity phenotype caused by polyQ expansions resulted in the identification of two FDA
approved drugs namely lithium chloride and mithramycin [53].
There are also C. elegans transgenic models that recapitulate Parkinson and Alzheimer´s diseases.
In the first case, overexpression of human a-synuclein causes neuronal and dendritic loss in the
worm [54] while in the second overexpression of  human b-amyloid peptide in muscle cells
resulting in intracellular amyloid deposits and subsequent paralysis [55]. As C. elegans has proved
to be the most powerful metazoan organism in high-throughput RNAi screens, this capacity should
be further applied to these Alzheimer and Parkinson´s models as well as other such as spinal
muscular atrophy or fragile X syndrome [56]. RNAi also offers an interesting approach for
additional pathologies with a clear neuronal and behavioral basis underlying their etiology that can
be recapitulated in C. elegans like ethanol or nicotine addiction among others.
C. elegans RNAi in aging research
25 years ago, Johnson and Wood proposed C. elegans as a suitable model for the genetic study of
longevity [57, 58]. These 25 years have revealed how truthful this prediction was as aging studies
on C. elegans have been one of the most successful achievements obtained using this model.
Aging is an ancient problem although the identification of mutations that modulate this process is
relatively recent. age-1(hx546) was the first recessive mutant allele described in C. elegans with
an increase in both mean and maximal life span without any additional phenotypes on timing of
larval molts, food uptake, movement or behavior [59, 60]. Since then, hundreds of different
gerontogenes have come to light.
Forward genetic screens and the subsequent characterization of the isolated mutants is the most
traditional approach to tackle a genetic feature. Since there are C. elegans mutants displaying an
increase in life span, longevity can be considered a genetic trait. However, longevity shows some
important limitations when it comes to dissecting it genetically. 1) It is a population phenotype; we
need an isogenic population of worms to generate a longevity curve, 2) It is a post reproductive
phenotype; therefore, once an increase in longevity has been identified, the worms are no longer
fertile and 3) we need several days, usually weeks, to establish the phenotype. Taken together,
extended life span is a not an easily manageable genetic marker. Klass described in 1983 a method
for the isolation of long-lived mutants in C. elegans [60]; a screen using longevity as the criteria
for selection; but due to all the problems listed previously, this strategy has not been very popular.
Therefore, most of the long-lived C. elegans mutants described in the literature were discovered
using a surrogate phenotype. In fact, after the description of the first long-lived mutant, different
phenotypes such as constitutive dauer larva formation, slow metabolism, thermotolerance, among
others, were associated with longevity [61-63]. Given this association, several mutants that had
been previously described using the aforementioned phenotypes, were tested successfully for
longevity [61]. Another approach employing this correlation was the use of associated phenotypes
as selection criteria in forward genetic screens. For instance, Muñoz et al searched for
thermotolerant mutants and the subpopulation raised from this screen, using the surrogate
phenotype, were tested for longevity and resulted in enrichment in long-lived mutants within the
subset of thermotolerant animals [64].
The impact of the RNA interference technique in the C. elegans community has been enormous
and the capability of RNAi by feeding has been particularly powerful. The possibility to do whole-
genome screens for longevity has probably been the most important contribution of the RNAi
technique to the field of C. elegans aging. With RNAi we eliminate the problem of aging being a
post-reproductive phenotype and the laborious genetic mapping when using aging as phenotype.
Between the end of 2002 and the beginning of 2003, two different RNAi screens scoring
chromosome I and II appeared in the literature identifying mitochondria as a key factor in
longevity modulation [65, 66]. Shortly after, two more RNAi screens expanding the number of
genes tested were reported using maximum life span as selectable marker: Kenyon and colleagues
screened around 70% of the worm genome identifying 29 long-lived phenotypes, 23 of which
were new gerontogenes [67]; Ruvkun and colleagues targeted more than 80% of C. elegans genes,
identifying 89 distinct clones that were found to increase longevity [68]. As a demonstration of the
impressive potential of the RNAi technique, one can compare the 52 gerontogenes reported since
the publication of the first long-lived mutant (age-1) in 1982 until 2000 with the more than 100
gerontogenes discovered in the RNAi screens reported in only these two papers [69]. Importantly,
genes belonging to known pathways previously described to affect longevity were represented on
these screens, as well as new others. Most of these gerontogenes were included in one of the
following three classes: 1) genes dependent on DAF-16, a transcription factor essential for the
modulation of longevity and the key factor of the insulin pathway, 2) genes that influence
respiration and 3) genes probably related with caloric restriction [67]. Only a few genes could not
easily fit in any of these categories, suggesting that the above-mentioned classes constituted the
main cellular pathways affecting longevity.
Genome-wide longevity RNAi screens have also been performed using surrogate phenotypes such
as resistance to oxidative stress followed by longevity analyses on the pre-selected clones [37].
Thus, the Ahringer library chromosome III and IV clones were screened for paraquat resistance (a
superoxide anion generator) identifying 608 resistant clones, 84 of which conferred an additional
increase on mean lifespan [37]. Astonishingly, 80 out of 84 clones had never been described as
gerontogenes before. Probably the reason for the striking difference with the Kenyon and Ruvkun
screens was the use of paraquat resistance as pre-selective criteria instead of the maximum
lifespan used in the two above-mentioned screens.
The number of overlapping results among those screens was surprisingly small. Only 3 matches
were present between the first two screens, and four matches between these two and the paraquat
screen. One reason that could explain this fact is the high number of false negatives when scoring
viable postembryonic mutant phenotypes on RNAi by feeding screens [14, 70]. Refractory cell
lineages and variability among RNAi screen protocols could explain this high number of false
negatives. On the other hand, the small number of overlapping genes suggests that screens of this
type are not yet saturated and many new genes remain to be identified as longevity modulators.
The plasticity of the RNAi technique offers interesting possibilities of application. For
instance, a problem with knock-out mutants is that genes can have more than one function along
different life stages. The lethality phenotype of some mutations could then mask their functions
later on development so only conditional mutations could shed information about the
postembryonic functions of the gene. To solve the problem of early lethality, Ruvkun and
colleagues designed a screen in which worms were fed only during adulthood with RNAi
constructs previously reported to cause embryonic lethal or larval arrest phenotype and selected
the clones with an enhanced maximum life span [71]. Surprisingly, this screen revealed four times
more gerontogenes than those reported in the whole genomic screens mentioned before. Another
example comes from the studies of Chen et al. using only 57 genes that cause RNAi-induced larval
arrest [70]. They found that nearly 50% of them were gerontogenes. Lethality or larval arrest are
phenotypes associated with some longevity genes: strong alleles of the IGF receptor daf-2 produce
L1 arrest and the null is lethal, so again this could be considered as screens using surrogated
phenotypes. This overrepresentation of long-lived genes could be a demonstration of the
prediction that aging control mechanisms must have pre-reproductive roles, which could be
subjected to natural selection [72].
The advantage of using RNAi to transiently knock-down the function of any given gene was
already used by Kenyon and colleagues to determine the timing requirements for insulin signaling
on longevity in C. elegans. They fed worms with daf-2 RNAi clones at different stages and
measured the effect on longevity and the results supported the importance of the pathway to
modulate life span only during the adulthood period [73]. The same lab used an interesting trick
looking for the opposite effects [65]. To perform RNAi only during larval development period,
they fed worms using RNAi against cco-1, which encodes a respiratory-chain component, only
during larval stages. When the worms become adults, they were transferred to dcr-1 RNAi plates,
an essential factor of the RNAi machinery, trying to avoid any residual effect of the RNAi. The
RNAi targeting cco-1 during larval stages was enough to produce different effects along adult
stage (longevity, less amount of ATP, etc).
In all of the screens previously mentioned RNAi also facilitated epistasis analyses. For example
most of the positive RNAi clones for longevity were tested later in a daf-16 background in order to
determine whether the increase in longevity was dependent on daf-16. In a similar way, but
looking for additive effects, they performed assays in a long-lived daf-2 mutant background or in
eat-2 mutant worms, a mutant that mimics caloric restriction.
Together, all these experiments contributed to assign the new gerontogenes to different known
pathways or to glimpse if they defined new pathways.
The conjunction of RNAi and aging has been productive in every sense. A recent work on aging
and the effect of respiration and mitochondria shows how a modified feeding strategy can
modulate the efficiency of silencing by dsRNA [72]. Mutations or knock-down by RNAi
inhibiting the expression of genes important for mitochondrial electron transport chain (ETC) can
produce an extended lifespan phenotype on C. elegans. This effect appears to be completely
opposite to the findings on humans where several mutations that compromise the normal function
of ETC provoke human life shortening diseases. A plausible explanation for this apparent
contradiction is that only under conditions of partial ETC disruption is the extension of lifespan
achieved, and the complete depletion of ETC has deleterious effects. To test this hypothesis the
researchers performed a protocol of feeding the worms with different dilutions of bacteria carrying
the dsRNA expressing vector and bacteria carrying the empty vector and found that the increase of
longevity was seen only between a certain ranges of dilutions. A similar approach trying to
modulate the effect of RNAi was reported before [17] but it seemed to have less robustness and
reproducible.
RNAi can also be used in combination with other ‘–omic’ approaches to uncover new functional
relations that help to build networks starting from pathways. One nice example is the work of
Dong et al [74]. Using a quantitative mass spectrometry approach they identified targets of the
insulin pathway by measuring abundance of proteins between different insulin mutant
backgrounds. Later they studied by RNAi the role of these putative targets on longevity. RNAi
also helped to validate putative genes controlled by daf-16 identified through a chromatin
immunoprecipitation (ChiP) analysis [75]. These two works, and all previously mentioned, are an
example of different approaches and achievements obtained thanks to RNAi, but they are not the
only ones. In less than 10 years, RNAi has become a technique with a really widespread use.
Indeed RNAi is used in almost every C. elegans paper. To get a sense on that, we searched for
longevity and elegans terms on PUBMED and we found that more than 60% of the papers used
RNAi. Yet another curious example of the role of dsRNA interference on longevity can be
illustrated with the fact that RNAi was used to produce one of the most long-lived worms ever
published [76]. In a weak allele daf-2 background with ablated gonads and feeding in daf-2 RNAi
during adulthood, Kenyon and collaborators obtained a worm that was able to live as much as six
times compared to wild type worms.
The benefits of RNAi for the aging field are innumerable but limitations also exist. One of the
major problems is the reduced or non-existent effect of RNAi on the C. elegans nervous system
(see above). The neuroendocrine control of longevity has been clearly demonstrated [77] but in the
whole genome screens for longevity genes there were no matches involving genes responsible for
sensory neuron development. So it is plausible that those classes of mutants are underrepresented
in the RNAi screens. Another limitation, although not formally an RNAi problem, but a screen
problem, is the use of maximum life span as selection criteria. The standard measurement of
longevity is average life span. An increase on this average can correlate or not with a clear
increase on maximum lifespan, so this class of gerontogenes is not likely going to be identified in
these screens.
The majority of the new gerontogenes identified in RNAi screens to date appear to belong to
previously described pathways. Therefore, so far RNAi has probably primarily contributed by
providing more complete descriptions of known longevity pathways, but has possibly not added
any major new discoveries within the intriguing longevity terra incognita. The future of RNAi on
the aging field in worms could come from different sources. For instance, the characterization of
RNAi hypersensitive C. elegans strains that allow effective RNAi in the nervous system will help
to identify those genes expressed in neurons that modulate longevity and that were not scored in
RNAi screens using wild type strains. On the other hand, the use of different surrogated
phenotypes to select clones to be tested for longevity could also help gerontogene discovery. This
improvement together with new genome-wide screens could saturate the system and give us a
more precise view of the different pathways that modulate longevity.
RNAi in C. elegans embryonic development
One of the challenges for modern biology is to understand how a living organism is made. The
inactivation (by forward or reverse genetics) of genes necessary for this process leads, by
definition, to an embryonic lethal phenotype. Embryonic development is composed of a series of
steps. Every step needs the previous one and is in turn needed for the next step to proceed.
Moreover different signalling pathways cross-regulate throughout development to build the typical
pattern for each organism. RNAi of genes producing an embryonic lethal phenotype allows this
complex process to be divided into discrete problems that can be analysed and understood.
In a first approach, full genome RNAi screens provide a list of genes involved in a specific process
like embryonic development [14, 70]. However this information is very general. Understanding
the function of every single gene involved in development requires a detailed phenotypical
analysis of its loss of function phenotype. Two techniques have emerged as very informative to
characterize the defects produced by inactivation of a single gene: Immunofluorescence and 4D
microscopy.
Immunofluorescence
The in-situ detection of a protein, using specific antibodies, reveals when and where the active
product of a gene is expressed. Immunofluorescence has been widely used to study embryogenesis
in different model organisms. In the particular case of C. elegans, embryos from mothers fed or
injected with a specific RNAi can be fixed and incubated with an antibody that specifically
recognizes the protein of interest. The localization of that antibody is then visualized with a
secondary antibody (bound to a fluorochrome) that specifically recognizes the first antibody.
Antibodies that recognize specific cell types, tissues, or structures in C. elegans embryos (like
pharynx, muscles, hypodermis…) are very useful as molecular markers to study C. elegans
development. Observation under the microscope of RNAi embryos stained with such antibodies
gives a good overview of what might have caused the lethal phenotype, tissues affected, pattern
defects, etc. Primary antibodies can be requested directly from the lab where were generated (in
general the C. elegans community is very cooperative). There are also companies and labs having
wide collections of C. elegans antibodies like the Sugimoto lab (www.cdb.riken.jp).  Transgenic
reporter lines expressing fluorescent proteins (e.g. GFP) in particular cell types can also be
similarly used.
The main limitations of the immunomicroscopy are the availability of good antibodies and the
static character of the information that it provides. Once you have a specific antibody, you may
learn which tissues are abnormal, absents or misplaced in your RNAi experiment, but there is no
information about the process by which this embryo lack an organ, misplaced a structure or
developed an abnormal tissue for example. This problem was solved with the development of the
4D-microscope [78-80]. This technique offers a dynamic view of a C. elegans embryo (WT,
mutant or RNAi) during development.
4D-microscopy
In 1983 Sulston and co-workers [81] described the complete embryonic cell lineage of C. elegans.
This nematode is unique among other biological model systems due to its invariant cell lineage.
This work was carried out by direct observation of single cells during the development of many
different embryos. Such an approach requires a great deal of patience and is not suitable for
routinely analyzing mutants or RNAi embryos.
The 4D microscope is a multifocal-plane, time-lapse video recording system. It allows the
recording of a developing embryo in multiple layers at constant time intervals. It documents all the
cells, mitosis, apoptosis, migrations, etc… in space and time. The only requirement is for the
microscope to be equipped with Nomarski optics (a 100x plan-apo objective, for example, gives a
very good resolution) and to be motorized in the Z-axis. Motorization in the X-Y axes is not
necessary since the egg is not moving and fits in the recording field. Since Nomarski optics allows
embryos to be visualised without any staining or labelling, RNAi embryos derived from N2 or the
RNAi supersensitive strain rff-3 can be directly visualized and analyzed using a simple
microscope. Keeping the embryos at a constant temperature during recording is highly
recommended since C. elegans embryos incubated at 20ºC develop 1.2 times slower than at 25ºC.
We routinely perform our recordings at 25ºC [82]. The standard protocol captures images in 25 to
30 planes at a temporal resolution of 30 to 60 seconds.
Most microscope companies offer specific software to control their microscopes. Different
routines can be programmed to acquire the images in space and time. Other commercial software
can be used to perform 4D-microscopy with any microscope. There are also free programs that can
be downloaded from http://elegans.swmed.edu/Software.html. This software is not really useful
without a system to document cell positions, cleavages and gradually build up the lineage tree.
Among the different programs that can be used to analyse recording and to generate the lineage,
there are three that are most commonly used in the C. elegans community: SIMI Biocell, Angler
and VirtualWorm-base. With big differences regarding the user display, all of them allow tracing
of the cell lineage for any embryo. This tree can be compared afterwards to a WT cell lineage or to
any other lineage from mutants or RNAi embryos.
Despite the big improvement these analysis software offer over manual lineaging, and the relative
ease of acquiring the necessary equipment, these systems still suffer from a major limitation - that
cell positions and cleavages have to be manually marked for every cell to build up the lineage. It
takes 4-5 days for a trained person to build the complete lineage of an embryo. Recently, an
automated cell lineage tracing system has been developed [83] to analyze the embryogenesis of
any C. elegans embryo. The system detects the fluorescence of histone-GFP fusion protein
labelled cells and nuclei with a confocal microscope to follow every cell and define the mitosis
events. In this system, experiments have to be performed on a histone-GFP transgenic worm. It is
necessary to use a confocal microscope, and although some manual editing is still required, the
analysis is fully automated (StarryNite software).
Functional and molecular analysis of embryogenesis in C. elegans using RNAi
After the completion of the C. elegans genome sequence the next question was how to connect the
DNA sequence of the worm to its development. It is important from a basic research point of view,
and also because more than a half of the genes in C. elegans have a human homologue.
Mutagenesis-based screens are typically designed to focus on genes that yield robust and easily
identifiable phenotype. The RNA-mediated interference (RNAi) as method to specifically
inactivate single genes is so far the best functional genomics tool available for studying C. elegans
development. RNAi provides a direct causal link between a gene and its cellular function. Despite
some small variability, large scales RNAi performed in different labs shows similar results.
Different C. elegans full genome RNAi screens have been performed in the last 5 years. About
15% of the C. elegans genes show a detectable RNAi phenotype and approximately half of those
may result (depending on the RNAi protocol) in embryonic lethality. The RNAi phenotype of each
gene is available publicly on Wormbase (www.wormbase.org).
Molecular analysis of the sequence of RNAi clones with an embryonic lethal phenotype show a
correlation between the phenotype and its degree of conservation and putative molecular function.
C. elegans genes with an orthologue in another eukaryote are more likely to have a detectable
RNAi phenotype than all other genes (21% versus 6%). In addition genes present in the genome as
single copy are more likely to have an RNAi phenotype than those present in more than one copy
(31% versus 12%). Regarding to the non-viable phenotype (embryonic or larval lethal or sterile),
52% of those genes have an orthologue in another eukaryote. This shows that similar essential
basal cellular machinery is common to all eukaryotes.
A look at the molecular function of the proteins coded by genes with a non-viable RNAi
phenotype shows this class is enriched for basic metabolism and maintenance of the cell (indeed,
51% of C. elegans orthologues of yeast essential genes have a non-viable phenotype). In contrast
genes that are involved in more complex processes that are expanded in metazoa are enriched for
viable postembryonic phenotypes (Figure 1). A closer analysis of the InterPro domains of genes
whose RNAi gives a phenotype reveals that genes with animal specific domains
(Immunoglobulin/major histocompatibility complex, collagen triple helix repeat, EGF-like
calcium-binding, etc…) are more likely to have a viable postembryonic phenotype. Whereas genes
with “ancient” domains, presents all along the evolution (Elongation factor, cyclin, Ubiquitin
domain, Zinc-finger, etc…) are enriched in the category of genes giving a non-viable phenotype.
The chromosomal location of genes with a non-viable phenotype shows they are enriched in large
regions of the clusters of chromosomes I, II and III. Notably, the X chromosome shows a lower
percentage of genes with a non-viable phenotype. Genes belonging to functional classes enriched
for non-viable phenotype (having orthologues in other organisms, no redundant in the genome,
with “ancient” domains and functioning in basic metabolism) are highly underrepresented on the
X chromosome. This seems to be related to the transcriptional repression of the X-linked genes in
the germ line and could have evolutionary benefits [70].
Phenotypical analysis of C. elegans embryos
The function of a gene is defined by its loss-of-function phenotype, since this shows the
physiological processes that the gene is required for. Understanding the function of all of the genes
that have an embryonic lethal phenotype implies the phenotypic analysis of their loss-of-function.
This can be achieved by combining the availability of the RNAi feeding libraries and the power of
4D microscopy.  The phenotypic analysis is performed by 4D-microscopy of F1 embryos from
worms fed or injected with RNAi. Ideally this has to be done for every RNAi clone giving an
embryonic lethal phenotype. The difficulty of such a screen is to perform several recordings for
each clone (to have reproducible data), to analyze and score every recording for different defect
categories. Several thousands of these recordings have been analyzed for the first few cell
divisions and the information has been standardized into phenotype classes [84] (Figure 2).
Among the 929 RNAi clones (5.5%) resulting in embryonic lethality, 661 of them show a defect in
the first two rounds of mitotic cell division after fertilization (called here early embryogenesis) in
laboratory conditions. A detailed database for all the phenotypes in the early embryogenesis can be
found at: http://www.worm.mpi-cbg.de/phenobank2/. Half of these genes are involved in cell
division processes such as chromosome segregation or cytokinesis, and the other half are needed
for cell maintenance processes such as translation and mitochondrial function.  This phenotypic
analysis allows a very broad and detailed view of cellular events but does not detect other more
subtle defects like chromosome segregation or protein misslocation. 4D microscopy using
fluorescently tagged markers in living embryos will help to detect and analyze such defects. As a
final comment concerning the use of RNAi to understand embryogenesis, we note that the number
of genes showing embryonic functions in the RNAi assay appears to be surprisingly low (~10%).
This probably does not primarily reflect a limitation of the technique, since the detection rate of
RNAi has been measured at 78% [17] . More likely this probably reflect the fact that the embryo
grows within a protective environment surrounded by an eggshell so allowing simplification of its
regulatory systems [84].
C. elegans RNAi in cancer research
Cancer genes and the pathways that they control
Alterations in three types of genes are responsible for tumorogenesis: oncogenes, tumor-
suppressor genes and stability genes. Unlike diseases such as cystic fibrosis or muscular
dystrophy, wherein mutations in one gene cause disease, no single gene defect causes cancer.
Mammalian cells have multiple safeguards to protect them against the potentially lethal effects of
cancer gene mutations, and only when several genes are defective does an invasive cancer
develop. Thus it is best to think of mutated cancer genes as contributing to, rather tan causing,
cancer [85].
Oncogenes are mutated in ways that render the gene constitutively active, or active under
conditions in which the wild-type gene is not. Oncogene activations can result from chromosomal
translocations, from gene amplifications or from subtle intragenic mutations affecting crucial
residues that regulate the activity of the gene product.
Tumor-suppressor genes are targeted in the opposite way by genetic alterations or mutations that
reduce the activity of the gene products. Such inactivation arises from missense mutations at
residues that are essential for its activity, from mutations that result in a truncated protein, from
deletions or insertions of various sizes, or from epigenetic silencing. Some recently described
tumor-suppressor genes have been hypothesized to exert a selective advantage on a cell when only
one allele is inactivated and the other remains functional (that is haploinsufficiency) [86].
However, mutations in both alleles are generally required to confer a selective advantage to the
cell.
Oncogene and tumor-suppressor gene mutations all operate similarly at the physiological level:
they drive the neoplastic process by increasing tumor cell number through the stimulation of cell
birth or the inhibition of cell death or cell-cycle arrest. The increase can be caused by activating
genes that drive the cell cycle, by inhibiting normal apoptotic processes or by facilitating the
provision of nutrients through enhanced angiogenesis.
A third class of cancer genes, called stability genes, promotes tumorogenesis in a completely
different way when mutated. This class included the mistmatch repair (MMR), nucleotide-excision
repair (NER) and base-excision repair (BER) genes responsible for repairing subtle mistakes made
during normal DNA replication or induced by exposure to mutagens. Stability genes keep genetic
alterations to a minimum, and thus when they are inactivated, mutations in other genes occur at a
higher rate [87].
As a result of research performed over the past decade, it is clear that there are many fewer
pathways than genes. This concept is very familiar to geneticists studying yeast, flies, mice and
worms - there are almost always a variety of genes that, when altered, lead to similar phenotypes.
Genes linked to human cancers often function in evolutionary conserved pathways, which allows
them to be studied in model systems [88, 89]. Although C. elegans does not form tumors per se,
other types of mutant phenotypes are clearly relevant for cancer research [90]. As a few examples,
there are mutants where cell division is unregulated (e.g. cki-1, a cycline kinase inhibitor and glp-
1, a Notch-like gene, mutants where cells that should undergo apoptosis fail to die (e.g. ced-3, a
caspase homolog, ced-9, a Bcl-2 homolog, and cep-1, a p53 homolog), and mutants where the
genome is unstable, generating spontaneous mutations (e.g., msh-2 and msh-6, mismatch repair
genes) [91]. Futreal et al (2004) recently compiled a list of 291 genes causally implicated in
human cancer by conducting a census of the literature [92]. When the subset of 61 of these cancer
genes with germline mutations were taken and searched for C. elegans homologues, 80% have a
putative worm homologue, and a mutant or RNAi phenotype has been reported for 53% of these
[92].
The standard genetic approach to investigating the function of a gene is to alter its activity.
Forward and reverse genetics have been successfully applied in the past for this purpose. With the
completion of numerous genome sequences, including C. elegans, Drosophila and mice, it became
possible to envisage comprehensively determining the functions of genes involved in cancer.  The
mouse model is one of the best because of the similarities between mouse and human tumors.
However, it has several disadvantages such as cost and space, and transgenic technologies are time
consuming and tedious [93]. These approaches become even more daunting if a gene function
must be studied in an appropriate multistep cancer context. An alternative is to use other model
organisms such as Xenopus, Drosophila, or C. elegans. These model organisms have contributed
importantly to our understanding of basic biological phenomena involved in the tumor cell
transformation [94].
Another approach to studying the function of cancer genes is to follow global patterns of gene
expression in tumors using microarray technology. This high-throughput technology identifies
genes that are up- or downregulated in tumors but cannot reveal gene function or define causal
roles for potential drug targets. RNAi interference (RNAi) allows such systematic studies, and is
therefore an ideal tool for high-throughput functional genomics.
Genome wide RNAi for cancer target identification
RNAi feeding libraries, which represent a large fraction of all genes of C. elegans genome, are
contained in 96-well plates and are therefore compatible with standard high throughput robotics.
The ‘whole genome’ collection of C. elegans nicely fits in 210 96-well plates. For screening,
dsRNA material or dsRNA-expressing bacteria are transferred to 6-, 12-, 24- or 96-well plates
containing C. elegans animals and phenotype are scored over the following several days. The
screening procedure itself is straightforward; the challenge lies in choosing the appropriate C.
elegans model and in developing and validating the corresponding assay.
In the last years more than 15 genome-wide screens have been performed in C. elegans scoring
over 40 different phenotypes. Many of these were performed in the wild-type strain. Other took
advantage of specific mutant backgrounds to develop more sensitive o selective assays [94].
Below, we consider two different screens in two important cancer pathways: (i) apoptosis, and (ii)
the RTK/Ras/Raf/MAPK signaling pathway.
 i. Apoptosis pathways: Apoptosis is a genetically regulated form of cell death that is
triggered by different stimuli. It is used to discard misbehaving cells, maintain homeostasis, and
eliminate cells during development. Misregulation of apoptosis can lead to a range of pathological
conditions, including cancer.
During C. elegans development, 131 cells undergo programmed cell death to produce the final 959
somatic cells in the hermaphrodite [95]. In addition, during oogenesis, about half of all germ cells
are eliminated by apoptosis [96]. As in other systems, apoptosis in C. elegans requires a caspase
(CED-3) and an Apaf-1 homologue (CED-4), and is blocked by a Bcl 2-like protein (CED9) [97].
DNA damage (such as radiation) causes an increase in germline cell deaths, and this requires the
C. elegans p53 orthologue cep-1 and the checkpoint gene hus-1 [98].
Two RNAi screens for genes involved in apoptosis have already been carried out. In the first,
authors screened for an increase in germline apoptosis; germline corpses are easily detected by
acridine orange staining followed by fluorescent microscopy. After screening 16757 genes, 21
were discovered where an RNAi knockdown causes excess deaths [99]. Of these, 16 were
previously unknown, including pmk-3, a p38 MAPK homologue, and bmk-1, a homologue of the
BimC gene involved in spindle formation. Even though the screening procedure identified just a
few of the expected known genes, it succeeds in finding new candidates. Interestingly, of the 21
genes identified, 16 require cep-1 (p53) and a functional DNA damage response pathway to
activate germ cell death; these genes might act in DNA repair or genome stability. In fact, the
screening identified homologues of RAD50 and RAD51, which are required for DNA repair and
meiotic recombination [100]. Of the five p53 independent genes found, one was ced-9, a regulator
of physiological germ cell death, suggesting that the other four genes may play a similar role [96].
A second group used a candidate-based functional genomic screen for apoptotic DNA degradation
in C. elegans [101]. Using INTERPRO and PFAM motifs to find genes corresponding to
deoxyribonucleases, ribonucleases, cyclophillins, and topoisomerases, they found 77 candidates
that were analyzed by TUNEL (terminal deosyribonucleotidyl transferase (TdT)-mediated biotin-
16-dUTP nick-end labeling) assay. RNAi of nine of these candidates were positive in that assay
and all of them have a human homologue. Candidate-based approaches that combine
bioinformatics with RNAi technology, such as those described above, are very powerful. They can
also be very rapid, since most of the selected candidates can be provided by the existing RNAi
library, avoiding the step of generating reagents.
 ii. RTK/Ras/Raf/MAPK signaling pathway: The RTK/Ras/Raf/MAPK signaling pathway
is highly conserved and is used in many contexts during animal development, but when
deregulated can lead to cancer. Mutations in K-, N. and H-ras mammalian gene have been
identified in many different tumors types. In particular, a high frequency of mutations in K-ras has
been detected in pancreatic (60-100%) and in colorectal (20-35%) tumors. In C. elegans, Ras
signaling has been most studied in the development of the vulva, the egg-laying organ, where Ras
activity is needed for adoption of the vulva cell fate. In mutants where Ras signaling is
hyperactivated, non-vulva cells are transformed to the vulva fate. This condition leads to ectopic
vulval development, visualized by the presence of multiple vulvae. The C. elegans vulva is an
excellent system for studying the regulation of the Ras signaling pathway [102]. Classical forward
genetic screens have identified numerous regulators of Ras signaling. Many of these screens
involved looking for enhancers or suppressors of altered Ras signaling. Repeating the classic
screens (e.g. suppressor or enhancer of activated Ras) using RNA interference will likely prove
effective in identifying additional regulators. An advantage of the RNAi screening approach is that
it can easily identify genes where loss-of-function mutants are non-viable; these can be difficult to
isolate in a standard genetic screen.
Chemical genetics and mechanisms of cancer drug action.
In classical or forward genetics, the genome of an organism is randomly mutagenized, and mutants
with the desired phenotype are collected and used to identify and characterize genes involved in
the process of interest [103]. Chemical genetics is a special type of genetic screen that makes use
of small-molecule compounds [104]. The principle is to screen for mutants that are either resistant
or hypersensitive to the effect of a compound. These mutants carry genetic alterations either in the
gene encoding the protein target or in other genes acting in the same pathway. Forward chemical
genetics can be used to identify the mode of action of natural product molecules or lead
compounds arising from phenotype screens. Identification of the target allows for the development
of assays to enable lead optimization or the identification of further chemical hits and leads. This
approach had been used to identify cellular targets of farnesyl transferase inhibitors (FTI). FTIs
block the post-translation modification of several proteins, including RAS, and have been
developed as anticancer drugs [105]. A number of these compounds have been shown to
specifically revert the phenotype of Ras gain-of-function in C. elegans mutants, suggesting that C.
elegans could serve as a model for Ras-dependent cancer [106]. A set of these compounds also
had pro-apoptotic activity against mammalian cells that do not carry oncogenic Ras mutations,
suggesting the presence of additional targets. RNAi screens were performed to identify 74 genes
that phenocopied FTI treatment. It is important to recognize that not all 74 genes can be targets of
these FTIs, it is likely that some modulate the FTI pathway only indirectly, some affect a C.
elegans-specific process, and others are involved in a general resistance mechanism. This
chemical genetic study both identified RabGGT as a novel target for cancer therapy and lead to a
better understanding of the mode of action of FTIs.
Chemotherapy and ionizing irradiation are the two mainly strategies utilized in the treatment of
cancer patients. The molecular mechanisms underlying the development of chemotherapy
resistance for the drugs more frequently used in the treatment of different tumors (i.e. 5-FU,
cisplatin, oxaliplatin, irinotecan, etc.) remain largely unknown. As example, fluoropyrimidine
agents are among the chemotherapeutic agents more currently utilized in the treatment of
colorectal cancer, in both adjuvant (after tumor surgery) and disseminated disease. These drugs,
including 5-fluorouracil (5-FU) and the pro-drug capecitabine have been clinically used during the
last 40 years. In spite of the low response rate of 5-FU as a single agent, only effective in around
20% of the treated cases, in localized disease the adjuvant 5-FU treatment is currently considered
the standard of care. 5-FU is an important drug also utilized in the treatment of other tumors:
breast, ovarian and head and neck tumors. Despite significant research on the effects of 5-FU in
cancer cells in vitro, the molecular mechanisms underlying the development of 5-FU resistance in
patients, a major cause of mortality in advanced cancer patients, remain largely unknown.
Resistance to fluoropyrimidines is a multifactorial event, which includes transport mechanisms,
metabolism, molecular mechanisms, protection from apoptosis and resistance via cell-cycle
kinetics.
In the last few years, several C. elegans research groups have been working either in the
characterization of the mechanisms of cellular response to irradiation or in understanding the
toxicity of different drugs. Recently, we have demonstrate that C. elegans is a suitable animal
model for: (i) the development of new Gleevec® (STI-571)-derived drugs, which is main drug
used in the treatment of chronic myelogenous leukemia (CML); and (ii) we have investigated the
genetic pathway regulated by the c-abl kinase in C. elegans [107]. Now, we have identified using
microarrays hundreds of genes involved in the worm response to 5-FU treatment, and we are
trying to identify by feeding dsRNAi which of these genes are involved in the resistance to 5-FU
treatments. Candidate genes can be validated in series of colorectal tumors with optimal follow up
and homogeneously chemotherapy treated (Martinez-Iniesta M and Villanueva A, unpublished
results). A better understanding of the cellular mechanisms of the resistance/sensitivity of these
drugs, using the model organism C. elegans, will be very useful to understand the drug resistance
mechanisms frequently observed in CRC Tumors (Colorectal Carcinoma), thus allowing an
improvement of patient chemotherapy treatment.
RNAi and systems biology
Systems biology can be defined as the study of all of the components of a biological system,
together with their interactions. The first impact of RNAi for systems biology has therefore been
the use of genome-wide RNAi screens to comprehensively identify the components of many
biological systems [108]. This approach has primarily been used in vivo in C. elegans and in
Drosophila cell culture.  For example, to date more than 40 different phenotypes have been
assayed in genome-wide RNAi screens in C. elegans (screens listed in [109]).  These phenotypes
cover a huge range of cellular, developmental and physiological processes ranging from the
components of cellular pathways [110], to the development of particular cells [84] and organs
[36], to whole animal phenotypes such as aging [67].  In this way RNAi screens can be considered
as ‘setting the stage’ for systems biology.
However in addition to the identification of components, RNAi is also starting to be used as a tool
for true systems analysis. Here we highlight two examples of the impact of RNAi on systems
biology, with particular respect to a systems analysis of genetics. First we discuss the use of RNAi
for understanding the global properties of genetic interaction networks – that is, how mutations
combine to produce phenotypes. Second we highlight the use of RNAi for benchmarking
integrated predictive gene networks.  Both of these approaches have been pioneered in C. elegans,
and both approaches should have major implications for a ‘systems understanding’ of the genetics
of human disease.
RNAi and systems biology 1: using RNAi to map genetic interaction networks
The relationship between the genotype of an organism and its phenotype is not a simple one-to-
one mapping between genes and phenotypes.  Rather phenotypes result from the interactions
between the products of many different genes [111].  From the point of view of human health, all
hereditary diseases in humans are probably genetically complex, resulting not from mutations in
single genes but from combinations of mutations in multiple genes that interact in a non-additive
manner [112].  For example even in the ‘simple monogenic’ disease, cystic fibrosis, it is not
possible to predict the clinical phenotype of a patient based solely on knowledge of the exact
mutation in the ‘Cystic Fibrosis Gene’, CFTR.  Indeed at least seven loci are known to modify the
clinical phenotype resulting from mutations in the CFTR gene [112]. Most human diseases are
genetically much more complex than cystic fibrosis and despite the recent flood of genome-wide
association studies, most of the demonstrated hereditary predisposition underlying these diseases
remains unexplained.  One of the main reasons for this is that many phenotypes are dependent
upon ‘synthetic’ interactions between mutations – mutations that alone can have little affect on a
disease phenotype can have great effects in combination [113] – and in genome-wide association
studies there is insufficient statistical power to identify these interactions between mutations [112].
The importance of genetic interactions in human disease, and our inability to predict these
interactions, has inspired recent work to systematically understand how mutations interact to
produce phenotypes. If we can globally understand how mutations interact to produce phenotypes
in model organisms, then we may be able to learn how to predict how mutations interact in human
disease.  Although there are many important types of aggravating and alleviating genetic
interactions that can occur between mutations [114], to date most work has concentrated on
synthetic lethal interactions because they are easy to identify in large-scale analyses. Formally a
synthetic (or synergistic) lethal interaction is defined when the fitness resulting from combining
two mutations is less than the product of the fitness of the two individual mutations.  In the
language of population genetics, these interactions are equivalent to negative epistasis.
The systematic mapping of synthetic lethal interactions has been pioneered in budding yeast where
synthetic interactions between mutations can be rapidly identified using the comprehensive
collection of yeast deletion strains.  In this approach a viable mutation is mated with the set of
viable deletion strains, the resulting diploid progeny are sporulated allowing the identification of
double mutant combinations that impair growth [115-117]. However in multicellular diploid
animals such an approach is not yet possible because complete gene deletion collections and
markers are not yet available to systematically construct homozygous double mutants.  However
the ease of inhibiting gene expression using RNAi has offered a powerful alternative approach.  In
particular C. elegans is a unique animal in which RNAi can be delivered in vivo by bacterial
feeding [13].  In this approach synthetic lethal interactions can either be identified by combining a
defined genetic mutation with RNAi targeting a second gene (Figure 3A) or by using
combinatorial RNAi to target two genes simultaneously (Figure 3B) [16]).  Although the
inhibition of gene expression resulting from the simultaneous inhibition of two genes by RNAi in
C. elegans is less effective than that seen when a single gene is targeted, these dilution effects are
reduced in RNAi hypersensitive strains [16].  To further facilitate the systematic identification of
genetic interactions, methods have been developed that allow RNAi screens to be performed in 96-
well plates [89, 118] using a bacterial feeding library [70]. An additional advantage of using RNAi
to identify genetic interactions is that because RNAi normally produces a ‘knock-down’ rather
than a ‘knock-out’, it is also possible to identify synthetic lethal interactions for essential genes
[119].
Using high-throughput RNAi screens in C. elegans, Lehner et al. recently constructed the first
systematic genetic interaction network for any animal [119].  They focused on genes that function
in signalling pathways, and tested >65,000 pairs of genes for their ability to interact in vivo using
both genetic mutant query strains and combinatorial RNAi.  In total they identified 351 pairs of
genes that when inactivated in combination produced a synthetic lethal phenotype (i.e. synthetic
sterility or synthetic embryonic lethality, Figure 3C). A second network, constructed using a lower
throughput but potentially more sensitive method has also recently been described, again focusing
on signal transduction genes [120].
One use of the data from these synthetic lethal screens is for the identification of new components
of important cellular pathways.  For example using their interaction data, Lehner et al. were able to
verify multiple novel modulators of the EGF/Ras/MAPK signalling [119] and Byrne et al.
identified new components of a pathway that regulates fat storage [120].  However perhaps a more
important use of these systematically compiled networks are the insights that they provide into the
global structure of genetic interaction networks, because these insights can be used to predict the
likely genetic structure of human disease.   For example, the most important insight of the yeast
synthetic lethal network is the shear size of the network – a typical gene interacted genetically
with many more genes than it’s product interacts physically with [117].  From the point of view of
any particular phenotype, the networks predict that there are probably many more ways to obtain a
phenotype by combining mutations in two genes than by mutating a single gene [117].  This
predicts that for most hereditary diseases there will also be more ways to cause the disease as a
result of mutations in two genes than as a result of a single mutation.  Indeed this may explain why
the known genetic mutations only explain a minority of known disease susceptibility, and that
current approaches to identifying human disease genes may be fundamentally flawed.
The systematic mapping of genetic interaction networks has also provided some more positive
insights for human disease.  One of these is the realization that mutations in some genes can
enhance the phenotypes resulting from mutations in many other functionally unrelated genes. For
example in the C. elegans genetic interaction network, inhibiting the expression of some genes
enhances the phenotypes resulting from mutations in genes from all of the signal transduction
pathways tested.  Interestingly all of these genes encoded components of chromatin modifying
complexes [119]. This finding predicts that in humans there will be similar ‘hub’ genes that when
inactivated will act as enhancers in multiple, mechanistically unrelated human diseases.  Insights
such as this are only possible using such systematic and global analyses.
RNAi and systems biology 2: using RNAi to benchmark integrated gene networks and using
integrated gene networks to guide RNAi screens
The central goal of genetics is to understand how changes in the genotype of an organism relate to
changes in its phenotype. A goal of systems biology is therefore to develop predictive methods
that comprehensively map this relationship between genotype and phenotype [111].  Genome-
wide RNAi screens have already made a major contribution to this effort by more
comprehensively identifying the genes that can be mutated to give a particular phenotype in a
complex animal [108]. The shear number of these screens that have been performed, and the
diversity of phenotypes that have been scored means that we can use this data to test
computational methods that globally connect genotypes to phenotypes. Such methods will be
essential for comprehensively understanding the biology of other species where in vivo reverse
genetic screens are not possible, especially humans.
One potential approach to the problem of predicting phenotype from genotype is to construct case-
by-case dynamic gene network models for the function or development of particular cells, tissue or
organ types [121]. However, in very few cases [122] do we yet understand the dynamics of a
system to make such an approach possible.  Moreover to construct case-by-case dynamic models
for each of the developmental and physiological systems of a complex animal is a formidable
problem.  An alternative approach is to construct non-dynamic ‘functional’ networks that cover
the whole proteome of an organism [123].  In these networks genes are connected if they are likely
to share a common biological function.  These networks can be used to globally connect genotype
to phenotypes because genes that share the same function are also likely to share the same loss-of-
function phenotypes.  The approach has been pioneered in budding yeast [124, 125], but a recent
study has used the extensive RNAi data available for C. elegans to demonstrate that the approach
will also work for a complex animal [109].
Many diverse functional genomic datasets can be used to predict genes that share biological
functions [123].  These include both direct physical associations (e.g. protein interactions), and
indirect associations (e.g. the co-expression of genes across conditions).  Moreover data can be
integrated from multiple different species using orthology relationships between genes.  However
each of these datasets is incomplete and of very different quality (ie each set contains varying
levels of false-negative and false-positive interactions).  The key to this approach is therefore to
first measure how good each dataset is, and then to combine the datasets with each dataset being
weighted according to its quality (Figure 4A).  The resulting network therefore connects genes that
are likely to share functions, with each interaction weighted according to its probability of being
correct.  This is normally achieved using a naïve or modified Bayesian integration of datasets
[124, 125].
In the first comprehensive application of this approach to an animal, Lee et al. have constructed a
probabilistic integrated gene network that covers >80% of C. elegans genes with ~400,000
interactions [109].  The datasets they used included protein interaction datasets from multiple
species, genetic interaction datasets, the co-expression of genes across multiple conditions, the co-
inheritance of genes across bacterial genomes, the tendency of genes to be in the same operons in
bacteria, and the co-citation of genes in the literature.  In total more than 20 million data points
were used in the construction of this network.  To benchmark each dataset the authors used the
Gene Ontology database [126] – each dataset was benchmarked according to its ability to connect
genes which share Gene Ontology annotations rather than genes which have different Gene
Ontology annotations.
The pivotal importance of RNAi for this approach has been the use of existing and new RNAi data
to test how well the networks can be used to connect changes in genotype to changes in
phenotype.  Importantly no RNAi phenotype data was used in the construction of the Lee et al.
network, so the authors could use all of the available RNAi screen data to test how well the
network connects changes in genotype to changes in phenotype.  Using precision-recall analysis,
the authors found that the network is predictive for 39 of 43 of the phenotypes that have ever been
screened in genome-scale studies.  Indeed for 29 of the phenotypes the network is excellently
predictive [109]. The authors also used new RNAi screens to demonstrate that the network can
also be used to predict genetic interactions between genes.  They focused on genes that when
mutated could suppress the consequences of mutations in the Retinoblastoma/synMuv pathway.
Starting with 6 genes known to share this ability, they were able to identify a further 16 genes by
testing the direct neighbours of these genes predicted by the network. Analysis of known synthetic
lethal interactions further demonstrates that these networks can also predict interactions between
mutations.
One application of these integrated functional networks is that they can be used to suggest a
manageable set of candidate genes to test by RNAi screens.  This approach, termed ‘network
assisted screening’ provides a great potential for systems where RNAi screens are more laborious
or expensive than in C. elegans.  Provided that some genes are known to affect a phenotype, then
the immediate neighbours of these genes in an integrated network can be used to predict additional
genes that will also affect the phenotype (Figure 4B).  Such an approach dramatically reduces the
number of genes that have to be screened to identify new regulators of a pathway or system.  For
example in the case of the Retinoblastoma pathway given above, using network assisted screening,
the number of genes that needed to be tested to identify a real suppressor was reduced over 20-fold
[109].
Network assisted screening also offers a great potential for human disease.  Starting with a limited
number of genes known to be causally mutated in a disorder, an integrated network can be used to
predict new candidates that can then be tested for their association with the disease in human
populations.  Such an approach has been demonstrated to be effective by simulation [127, 128]
and most recently has been used to identify a novel breast cancer susceptibility locus [129].
Caenorhabditis elegans: A view of a top model from the “In vivo Science Parade”. Closing
Remarks.
Advances in genomic sequencing technologies and the development of high throughput strategies
made possible the completion of the human genome sequence at the beginning of the 21st century
[130, 131]. With its publication, a new and promising post-genomic Era came to life and with it,
many new opportunities, but also many new challenges such as data interpretation and the
identification of new genes and genomic structures. Nonetheless, a large number of genes and
genomic profiles potentially involved in diverse human diseases are constantly appearing as new
actors on the three-dimensional playground of human cell fate and biochemical homeostasis. Such
an amount of data and the lack of knowledge of how genes interact with each other to define
functional genomic networks have pushed forward the use of experimental in vivo models.
Particularly, C. elegans may provide the fundamental complexity of a multicellular organism
appropriate for understanding the molecular basis of human disease and therefore may prove a key
tool in the development of new therapies.
The complete genomic sequence of C. elegans was reported in 1998 [1]. Approximately 65% of
human disease-related genes have a C. elegans counterpart [41, 132-134]. This is also true for 60-
80% of total human genes [1], and many of the major human disease related signal transduction
pathways such as those from Ras, Wnt, Notch, TGF-beta, mismatch repair, DNA damage response
and apoptosis are remarkably well conserved in C. elegans.
In 2006 the Nobel Prize for Physiology and Medicine was awarded for the discovery of RNA
interference (RNAi) in C. elegans. This ancient system to inhibit gene expression most likely
evolved as a protection from viral and other mobile sequences. However the experimental use of
RNAi has opened a new dimension for functional genomics in the worm and other systems,
including human cells. However because RNAi in C. elegans is systemic (dsRNA is actively
transported between all cells), very effective, free from non-specific effects, can be performed in
microtiter plates, and can be delivered by simply feeding the animals with E. coli bacteria
expressing dsRNA, the worm represents a uniquely powerful system for the rapid in vivo analysis
of gene function in a multicellular animal.  Indeed the free-availability and low-cost of the RNAi
libraries and the sharing of data between labs are features of the C. elegans community that other
researchers would greatly benefit from copying.  As a result, genome-wide screens have been
performed in C. elegans for the identification of genes implicated in almost every specific pathway
of interest to C. elegans researchers allowing the definition of whole networks of cell signaling
pathways.
In this context, inhibition of growth control genes that generate a tumor-like phenotype in worms,
can be regarded as potential tumor suppressor genes when considering their human homologues
[91]. Further, double mutants reverting the phenotype could be regarded as potential therapeutic
targets. Redundant pathways can be dissected in the same way, as well as potential genes
responsible of conferring resistance to certain drugs or treatments, opening the door to the use of
C. elegans in drug discovery and for the identification of genetic modifier genes [135-137]. The
use of RNAi strategies has become a powerful tool to establish whole three-dimensional signaling
interactive networks. In fact, different bioinformatic and system biology approaches have been
used to define a set of genes that are able to control several pathways acting as genetic hubs.
Indeed, genetic hubs can act as enhancers of other mutated genes belonging to different alternative
pathways [111]. A nice example concerning sets of chromatin-modifying genes was recently
reported [119].
Moreover, in the absence of a specific phenotype to screen for, specific reporter assays can be
designed and introduced into the animal by microinjection. As an example, new DNA repair genes
involved in microsatellite instability, a genome-wide alteration of tumors arising in patients with
hereditary non-polyposis colorectal cancer syndrome (HNPCC), were recently described [138]. An
out of frame GFP/LacZ vector was used for this purpose [139]. Mutations caused by generation of
a DNA mismatch repair defect by RNAi resulted in a new in-frame vector able to express a
GFP/LacZ open reading frame. Identification of worms expressing the fusion protein allowed the
identification of 61genes from which 13 proved to result in genomic instability when inhibited.
Among those, the 4 genes already known to be causing HNPCC were identified, providing a
strong proof of concept of the power of this approach in biomedical research. In a world where the
development of new therapies has become an urgent need, understanding gene function is
regarded as a crucial battle. In the middle, a small worm fed by bacteria might be our best ally.
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Figure legends
Figure 1. Relative amount of different functional classes with a Non-viable RNAi phenotype.
The line indicates the reference of 1.0. (Adapted from Kamath et al. 2003).
Figure 2. Phenotype classes showing biological events along embryonic development. Number
of genes included in each class is given in parenthesis. (Adapted from Sönnichsen et al. 2005).
Figure 3. Using RNAi to map genetic interaction networks. RNAi can be used to systematically
understand how mutations combine to produce phenotypes.  A synthetic lethal or sick interaction
(negative epistasis) is defined when the fitness resulting from the inhibition of two genes
simultaneously is much less than that expected from the fitness of the two individual mutations.
Synthetic lethal interactions can be systematically identified by either (A) combining genetic
mutants with RNAi or (B) using combinatorial RNAi [16].  (C) An example genetic interaction
between a mutation in the gene sos-1 and inhibition of the gene sem-5.  Alone each perturbation
has very little effect, but the combined perturbation results in sterile worms [119].
Figure 4. Constructing and using integrated gene networks: network assisted genetic screens.
(A) Integrated functional networks connect genes by interactions if two genes are likely to share
the same function [123].  Each functional or comparative genomic dataset is first measured for its
ability to connect genes that are known to share the same functional annotations, for example
using the Gene Ontology (GO) database [126]. The interactions predicted by each dataset are then
integrated together, but weighted according to how well each dataset performs in the
benchmarking [109].  In the example dataset 1 performs well and so interactions predicted by this
dataset receive high confidence scores, dataset 4 performs very poorly and so interactions
predicted by this dataset receive low confidence scores.  The final integrated network is therefore
probabilistic with each interaction having an attached likelihood score (here dark think lines
represent high-confidence interactions).  (B) These integrated networks can be used to predict
genes that will share the same loss-of-function phenotypes [109].  Starting with a set of genes
known to be associated with a phenotype, process or disease (seed genes), the rest of the proteome
is ranked according to the connectivity of each gene to the known genes in the integrated network.
The highest-ranking genes (candidate genes) can then be tested for their association with the
phenotype.  This dramatically reduces the number of genes that need to be tested to identify new
genes associated with a phenotype, process or disease.
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